SOHO Brazil 2024
A

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

By SOHO Brazil 2024 FEATURING Andrew Zelenetz
By SOHO Brazil 2024 FEATURING Andrew Zelenetz
466 views
July 11, 2024
0 Comments
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Lymphoma Highlights"

Feat. B. D. Cheson
13:07
Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez
22:09
Scripps Health

New Updates in Frontline DLBCL

Feat. L. Nastoupil
27:47
Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith
35:27
Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard
04:04
Wojciech Jurczak

Polatuzumab Vedotin for 1L DLBCL: Results From the POLARIX Trial

10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

09:18
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…

Feat. J. Westin
08:01
Georg Lenz

Treatment Landscape in 1L DLBCL: Polatuzumab Vedotin as SoC

20:34
UChicago Medicine

Sequencing of Bispecifics With Other Therapies in DLBCL

Feat. E. Budde
08:23
Total Health

R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment

Feat. J. Chandler, B. Randolph, M. Onciu
30:07
Dipenkumar Modi

Current Management of DLBCL From Frontline to Relapsed Disease

35:24
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

Feat. G. Nowakowski
17:07
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their…

Feat. M. Minnema
34:36
MyCancerHaven

Frontline DLBCL Treatment Approaches

Feat. R. Vij, H. Cherng
28:33
XIV Eurasian Hematology-Oncology Congress - EHOC 2023

The Truth About Current Consensus Statements on Hematopoietic Cell T…

Feat. R. Gale
16:34
Jennifer Amengual

Top 5 Lymphoma Abstracts From ASH

29:26
Massachusetts General Hospital Cancer Center

Practice-Changing Updates in DLBCL and HL

Feat. J. Erika Haydu
15:26
Moffitt Cancer Center

R/R DLBCL: Are CAR-Ts Superior to Bispecific Antibodies?

Feat. A. Lazaryan